The Co-Investor Question: Why Capital Alone Does Not Build Biotech Winners
In biotech, the right co-investor determines success.
Peter M. Kovacs explains why alignment, execution discipline, and operational de-risking matter more than capital alone in building resilient, high-performing biotech and MedTech companies.
Europe’s Deep Tech Paradox: World-Class Science, Invisible Companies
In this article, Dr. Peter M. Kovacs draws on his discussion with Thijmen Meijer and Károly Szántó to explain why Europe’s startup gap is not a capital shortage but a translation failure, and sets out what must change to convert scientific excellence into globally competitive deep-tech companies.